Luke Walker, MD

Dr. Luke Walker is the Chief Medical Officer at Umoja Biopharma, a clinical-stage leader in in vivo cell therapies focused on unlocking the full potential of CAR T cells. With over 20 years of experience in hematology and clinical development, Dr. Walker oversees Umoja’s clinical, regulatory, and medical functions, including its two clinical-stage in vivo CAR T cell programs, UB-VV111 and UB-VV400, targeting B cell malignancies.

Before joining Umoja, Dr. Walker served as Chief Medical Officer at Harpoon Therapeutics, where he led the company’s immune-oncology efforts through its acquisition by Merck in 2024. His previous roles include clinical development leadership at Seagen, Cascadian Therapeutics, and Oncothyreon. Earlier in his career, Dr. Walker was a practicing oncologist at The Everett Clinic and completed a hematology-oncology fellowship at Oregon Health & Science University, where he also completed his residency in internal medicine. He earned his M.D. from the University of Oklahoma College of Medicine.